Scientists Unmask a Master Gene Driving Aggressive Skin Cancer

NEW YORK, NY – February 11, 2026 – In a significant breakthrough for oncology, researchers have identified a single molecule that acts as a master coordinator for skin cancer, simultaneously fueling its aggressive growth and cloaking it from the body's immune defenses. The discovery, led by a team at NYU Langone Health and its Perlmutter Cancer Center, pinpoints the transcription factor HOXD13 as a critical driver in melanoma and unveils a promising new strategy to combat the deadly disease.

The study, published in the prestigious journal Cancer Discovery, details how HOXD13 orchestrates a two-pronged assault. It promotes the growth of new blood vessels that feed the tumor—a process called angiogenesis—while also creating an immunosuppressive shield that prevents cancer-killing T cells from reaching and destroying it. This dual function makes HOXD13 a particularly powerful adversary, but also a uniquely valuable target for future therapies.

The Dual-Threat Molecule

At the heart of the discovery is HOXD13, a type of protein known as a transcription factor, which controls how genetic instructions are used to build other proteins. While normally involved in embryonic development, the researchers found that when overactive in melanoma, it becomes a potent oncogene.

The international team, with collaborators from the U.S., Brazil, and Mexico, analyzed tumors from over 200 melanoma patients and found HOXD13 to be a standout player. Their experiments revealed that the molecule directly stimulates pathways essential for tumor survival. It ramps up the production of vascular endothelial growth factor (VEGF), a key signal for angiogenesis, ensuring the tumor gets the oxygen and nutrients it needs to expand.

Simultaneously, HOXD13 sabotages the immune system's ability to fight back. It boosts levels of another protein, CD73, which in turn increases the concentration of a substance called adenosine in the tumor's immediate vicinity. Adenosine acts like a powerful brake on the immune system, effectively creating a force field that stops cytotoxic T cells—the body's elite cancer-fighting soldiers—from infiltrating and attacking the tumor. Experiments confirmed that suppressing HOXD13 activity not only caused tumors to shrink but also allowed an influx of T cells.

"Our study provides new evidence that transcription factor HOXD13 is a potent driver of melanoma growth and that it suppresses the T cell activity needed to fight the disease," said study lead investigator Pietro Berico, PhD, a postdoctoral research fellow at the NYU Grossman School of Medicine.

A New Strategy for a Shifting Battlefield

This deeper understanding of melanoma's inner workings has immediate therapeutic implications. The current landscape of melanoma treatment has been revolutionized by immunotherapies like PD-1 inhibitors (Keytruda, Opdivo) and targeted drugs for patients with BRAF mutations. While these have saved countless lives, a significant portion of patients—up to 50%—either don't respond to these treatments or eventually relapse as their cancer develops resistance.

The discovery of HOXD13's central role offers a new playbook. Instead of targeting single pathways, the researchers propose a combination attack that dismantles both the tumor's supply lines and its defenses.

"This data supports the combined targeting of angiogenesis and adenosine-receptor pathways as a promising new treatment approach for HOXD13-driven melanoma," stated study senior investigator Eva Hernando-Monge, PhD, a professor at the NYU Grossman School of Medicine.

The proposed strategy involves using a combination of drugs: one to block the VEGF pathway, cutting off the tumor's blood supply, and another to block adenosine receptors, thereby disabling its immune shield. This would leave the cancer starved and vulnerable to an immune attack, potentially overcoming the resistance seen with current therapies.

From Lab Bench to Precision Medicine

The path from this discovery to a new treatment is clearer than for many other basic science findings. This is because drugs that inhibit both VEGF and adenosine receptors are already in development and, in some cases, in separate clinical trials for various cancers. The NYU Langone team’s findings provide a strong rationale for combining them specifically for melanoma patients whose tumors show high levels of HOXD13.

If the ongoing trials for these individual inhibitors prove successful, Dr. Hernando-Monge says her team plans to initiate clinical investigations into the combination therapy. This represents a major step toward a new era of precision medicine for melanoma, where treatment is tailored not just to a broad cancer type, but to the specific molecular drivers within an individual patient's tumor.

Identifying these patients would be the first step, requiring a diagnostic test to measure HOXD13 levels. This targeted approach ensures that the powerful combination therapy is given to those most likely to benefit, while sparing others from potential side effects. While the promise is immense, the journey will involve carefully designed clinical trials to establish the safety and efficacy of the dual-inhibition strategy.

Beyond Melanoma: A Potential Ripple Effect

The implications of HOXD13's role as a cancer driver may extend far beyond melanoma. As a transcription factor from the HOX gene family, it belongs to a class of proteins known to be fundamental to cell development and, when dysregulated, to cancer.

Indeed, research has already implicated HOXD13 in other aggressive malignancies. In Ewing sarcoma, a devastating bone and soft tissue cancer, the molecule is known to be abnormally over-expressed and contributes to the tumor's ability to grow and spread. Similarly, studies have linked high HOXD13 expression in colon cancer to a poorer prognosis, where it appears to drive cell proliferation and invasion.

This broader context reinforces the significance of the NYU Langone findings. Dr. Hernando-Monge's team already plans to investigate whether the VEGF and adenosine pathways are viable targets in other cancers where HOXD13 is a known culprit, including some glioblastomas, sarcomas, and osteosarcomas. Unmasking HOXD13 as a master coordinator in melanoma may have provided a key that unlocks new treatment strategies for a host of other difficult-to-treat cancers.